Metabolic Risk Factors for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study
Non-alcoholic fatty liver disease (NAFLD) is a fast-growing public health problem and predisposes to hepatocellular carcinoma (HCC) in a significant proportion of patients. Metabolic alterations might underlie the progression of NAFLD to HCC, but the magnitudes of risk and population-attributable ri...
Gespeichert in:
Veröffentlicht in: | Cancers 2022-12, Vol.14 (24), p.6234 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 24 |
container_start_page | 6234 |
container_title | Cancers |
container_volume | 14 |
creator | Antwi, Samuel O Craver, Emily C Nartey, Yvonne A Sartorius, Kurt Patel, Tushar |
description | Non-alcoholic fatty liver disease (NAFLD) is a fast-growing public health problem and predisposes to hepatocellular carcinoma (HCC) in a significant proportion of patients. Metabolic alterations might underlie the progression of NAFLD to HCC, but the magnitudes of risk and population-attributable risk fractions (PAFs) for various metabolic conditions that are associated with HCC risk in patients with NAFLD are unknown. We investigated the associations between metabolic conditions and HCC development in individuals with a prior history of NAFLD. The study included 11,245 participants in the SEER-Medicare database, comprising 1310 NAFLD-related HCC cases and 9835 NAFLD controls. We excluded individuals with competing liver diseases (e.g., alcoholic liver disease and chronic viral hepatitis). Baseline pre-existing diabetes mellitus, dyslipidemia, obesity, hypertension, hypothyroidism, and metabolic syndrome were assessed. Multivariable-adjusted logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). PAFs were also calculated for each metabolic condition. The results show that diabetes (OR = 2.39, 95% CI: 2.04-2.79), metabolic syndrome (OR = 1.73, 95% CI: 1.49-2.01), and obesity (OR = 1.62, 95% CI: 1.43-1.85) were associated with a higher HCC risk in individuals with NAFLD. The highest PAF for HCC was observed for pre-existing diabetes (42.1%, 95% CI: 35.7-48.5), followed by metabolic syndrome (28.8%, 95% CI: 21.7-35.9) and obesity (13.2%, 95% CI: 9.6-16.8). The major predisposing factors for HCC in individuals with NAFLD are diabetes mellitus, metabolic syndrome, and obesity, and their control would be critically important in mitigating the rising incidence of NAFLD-related HCC. |
doi_str_mv | 10.3390/cancers14246234 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9777437</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A745273678</galeid><sourcerecordid>A745273678</sourcerecordid><originalsourceid>FETCH-LOGICAL-c488t-4c7dc7ba1581cd94e9f26a80ff6a333e269af1af12f68a704a1722fc6d2918543</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiNERau2Z27IEhcu28YfsRMOSKuFpUgLVC2crVln3HVJ4sV2ipZfj7dftFVtS7bGz7wev5qieE3LI86b8tjAYDBEKpiQjIsXxR4rFZtI2YiXD867xWGMl2UenFMl1atil8uqooo2e8Xfr5hg6TtnyJmLv8gcTPIhEusDOcE1JG-w68YOAplBMG7wPRA3kFNIDocUyR-XVuSbH6AzfnWtM4eUNmThrjCQjy4iRHxPpuQ0-LhGk3KcnKex3RwUOxa6iIe3-37xc_7px-xksvj--ctsupgYUddpIoxqjVoCrWpq2kZgY5mEurRWAuccmWzA0ryYlTWoUgBVjFkjW9bQuhJ8v_hwo7selz22JpcdoNPr4HoIG-3B6cc3g1vpC3-lG6WU4CoLvLsVCP73iDHp3sWtLTCgH6NmKpdWirraom-foJd-DNmca0pKWVey-U9dQIfaDdbnd81WVE-VqJjiUtWZOnqGyrPF3hk_oHU5_ijh-CbBZKtjQHv_R1rqbcfoJx2TM948tOaev-sP_g-HlL3M</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2756668569</pqid></control><display><type>article</type><title>Metabolic Risk Factors for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Antwi, Samuel O ; Craver, Emily C ; Nartey, Yvonne A ; Sartorius, Kurt ; Patel, Tushar</creator><creatorcontrib>Antwi, Samuel O ; Craver, Emily C ; Nartey, Yvonne A ; Sartorius, Kurt ; Patel, Tushar</creatorcontrib><description>Non-alcoholic fatty liver disease (NAFLD) is a fast-growing public health problem and predisposes to hepatocellular carcinoma (HCC) in a significant proportion of patients. Metabolic alterations might underlie the progression of NAFLD to HCC, but the magnitudes of risk and population-attributable risk fractions (PAFs) for various metabolic conditions that are associated with HCC risk in patients with NAFLD are unknown. We investigated the associations between metabolic conditions and HCC development in individuals with a prior history of NAFLD. The study included 11,245 participants in the SEER-Medicare database, comprising 1310 NAFLD-related HCC cases and 9835 NAFLD controls. We excluded individuals with competing liver diseases (e.g., alcoholic liver disease and chronic viral hepatitis). Baseline pre-existing diabetes mellitus, dyslipidemia, obesity, hypertension, hypothyroidism, and metabolic syndrome were assessed. Multivariable-adjusted logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). PAFs were also calculated for each metabolic condition. The results show that diabetes (OR = 2.39, 95% CI: 2.04-2.79), metabolic syndrome (OR = 1.73, 95% CI: 1.49-2.01), and obesity (OR = 1.62, 95% CI: 1.43-1.85) were associated with a higher HCC risk in individuals with NAFLD. The highest PAF for HCC was observed for pre-existing diabetes (42.1%, 95% CI: 35.7-48.5), followed by metabolic syndrome (28.8%, 95% CI: 21.7-35.9) and obesity (13.2%, 95% CI: 9.6-16.8). The major predisposing factors for HCC in individuals with NAFLD are diabetes mellitus, metabolic syndrome, and obesity, and their control would be critically important in mitigating the rising incidence of NAFLD-related HCC.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14246234</identifier><identifier>PMID: 36551719</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Codes ; Complications and side effects ; Diabetes ; Diabetes mellitus ; Dyslipidemia ; Enrollments ; Fatty liver ; Health aspects ; Hepatitis ; Hepatitis C ; Hepatocellular carcinoma ; Hepatoma ; Hypothyroidism ; Kidney diseases ; Liver cancer ; Liver cirrhosis ; Liver diseases ; Medicare ; Metabolic disorders ; Metabolic syndrome ; Metabolism ; Obesity ; Public health ; Risk factors ; Surveillance</subject><ispartof>Cancers, 2022-12, Vol.14 (24), p.6234</ispartof><rights>COPYRIGHT 2022 MDPI AG</rights><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c488t-4c7dc7ba1581cd94e9f26a80ff6a333e269af1af12f68a704a1722fc6d2918543</citedby><cites>FETCH-LOGICAL-c488t-4c7dc7ba1581cd94e9f26a80ff6a333e269af1af12f68a704a1722fc6d2918543</cites><orcidid>0000-0002-8912-9059 ; 0000-0003-2891-3082 ; 0000-0001-7021-9532</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777437/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777437/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36551719$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Antwi, Samuel O</creatorcontrib><creatorcontrib>Craver, Emily C</creatorcontrib><creatorcontrib>Nartey, Yvonne A</creatorcontrib><creatorcontrib>Sartorius, Kurt</creatorcontrib><creatorcontrib>Patel, Tushar</creatorcontrib><title>Metabolic Risk Factors for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Non-alcoholic fatty liver disease (NAFLD) is a fast-growing public health problem and predisposes to hepatocellular carcinoma (HCC) in a significant proportion of patients. Metabolic alterations might underlie the progression of NAFLD to HCC, but the magnitudes of risk and population-attributable risk fractions (PAFs) for various metabolic conditions that are associated with HCC risk in patients with NAFLD are unknown. We investigated the associations between metabolic conditions and HCC development in individuals with a prior history of NAFLD. The study included 11,245 participants in the SEER-Medicare database, comprising 1310 NAFLD-related HCC cases and 9835 NAFLD controls. We excluded individuals with competing liver diseases (e.g., alcoholic liver disease and chronic viral hepatitis). Baseline pre-existing diabetes mellitus, dyslipidemia, obesity, hypertension, hypothyroidism, and metabolic syndrome were assessed. Multivariable-adjusted logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). PAFs were also calculated for each metabolic condition. The results show that diabetes (OR = 2.39, 95% CI: 2.04-2.79), metabolic syndrome (OR = 1.73, 95% CI: 1.49-2.01), and obesity (OR = 1.62, 95% CI: 1.43-1.85) were associated with a higher HCC risk in individuals with NAFLD. The highest PAF for HCC was observed for pre-existing diabetes (42.1%, 95% CI: 35.7-48.5), followed by metabolic syndrome (28.8%, 95% CI: 21.7-35.9) and obesity (13.2%, 95% CI: 9.6-16.8). The major predisposing factors for HCC in individuals with NAFLD are diabetes mellitus, metabolic syndrome, and obesity, and their control would be critically important in mitigating the rising incidence of NAFLD-related HCC.</description><subject>Codes</subject><subject>Complications and side effects</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Dyslipidemia</subject><subject>Enrollments</subject><subject>Fatty liver</subject><subject>Health aspects</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatocellular carcinoma</subject><subject>Hepatoma</subject><subject>Hypothyroidism</subject><subject>Kidney diseases</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Medicare</subject><subject>Metabolic disorders</subject><subject>Metabolic syndrome</subject><subject>Metabolism</subject><subject>Obesity</subject><subject>Public health</subject><subject>Risk factors</subject><subject>Surveillance</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkk1v1DAQhiNERau2Z27IEhcu28YfsRMOSKuFpUgLVC2crVln3HVJ4sV2ipZfj7dftFVtS7bGz7wev5qieE3LI86b8tjAYDBEKpiQjIsXxR4rFZtI2YiXD867xWGMl2UenFMl1atil8uqooo2e8Xfr5hg6TtnyJmLv8gcTPIhEusDOcE1JG-w68YOAplBMG7wPRA3kFNIDocUyR-XVuSbH6AzfnWtM4eUNmThrjCQjy4iRHxPpuQ0-LhGk3KcnKex3RwUOxa6iIe3-37xc_7px-xksvj--ctsupgYUddpIoxqjVoCrWpq2kZgY5mEurRWAuccmWzA0ryYlTWoUgBVjFkjW9bQuhJ8v_hwo7selz22JpcdoNPr4HoIG-3B6cc3g1vpC3-lG6WU4CoLvLsVCP73iDHp3sWtLTCgH6NmKpdWirraom-foJd-DNmca0pKWVey-U9dQIfaDdbnd81WVE-VqJjiUtWZOnqGyrPF3hk_oHU5_ijh-CbBZKtjQHv_R1rqbcfoJx2TM948tOaev-sP_g-HlL3M</recordid><startdate>20221217</startdate><enddate>20221217</enddate><creator>Antwi, Samuel O</creator><creator>Craver, Emily C</creator><creator>Nartey, Yvonne A</creator><creator>Sartorius, Kurt</creator><creator>Patel, Tushar</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8912-9059</orcidid><orcidid>https://orcid.org/0000-0003-2891-3082</orcidid><orcidid>https://orcid.org/0000-0001-7021-9532</orcidid></search><sort><creationdate>20221217</creationdate><title>Metabolic Risk Factors for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study</title><author>Antwi, Samuel O ; Craver, Emily C ; Nartey, Yvonne A ; Sartorius, Kurt ; Patel, Tushar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c488t-4c7dc7ba1581cd94e9f26a80ff6a333e269af1af12f68a704a1722fc6d2918543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Codes</topic><topic>Complications and side effects</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Dyslipidemia</topic><topic>Enrollments</topic><topic>Fatty liver</topic><topic>Health aspects</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatocellular carcinoma</topic><topic>Hepatoma</topic><topic>Hypothyroidism</topic><topic>Kidney diseases</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Medicare</topic><topic>Metabolic disorders</topic><topic>Metabolic syndrome</topic><topic>Metabolism</topic><topic>Obesity</topic><topic>Public health</topic><topic>Risk factors</topic><topic>Surveillance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Antwi, Samuel O</creatorcontrib><creatorcontrib>Craver, Emily C</creatorcontrib><creatorcontrib>Nartey, Yvonne A</creatorcontrib><creatorcontrib>Sartorius, Kurt</creatorcontrib><creatorcontrib>Patel, Tushar</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Antwi, Samuel O</au><au>Craver, Emily C</au><au>Nartey, Yvonne A</au><au>Sartorius, Kurt</au><au>Patel, Tushar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metabolic Risk Factors for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2022-12-17</date><risdate>2022</risdate><volume>14</volume><issue>24</issue><spage>6234</spage><pages>6234-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Non-alcoholic fatty liver disease (NAFLD) is a fast-growing public health problem and predisposes to hepatocellular carcinoma (HCC) in a significant proportion of patients. Metabolic alterations might underlie the progression of NAFLD to HCC, but the magnitudes of risk and population-attributable risk fractions (PAFs) for various metabolic conditions that are associated with HCC risk in patients with NAFLD are unknown. We investigated the associations between metabolic conditions and HCC development in individuals with a prior history of NAFLD. The study included 11,245 participants in the SEER-Medicare database, comprising 1310 NAFLD-related HCC cases and 9835 NAFLD controls. We excluded individuals with competing liver diseases (e.g., alcoholic liver disease and chronic viral hepatitis). Baseline pre-existing diabetes mellitus, dyslipidemia, obesity, hypertension, hypothyroidism, and metabolic syndrome were assessed. Multivariable-adjusted logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). PAFs were also calculated for each metabolic condition. The results show that diabetes (OR = 2.39, 95% CI: 2.04-2.79), metabolic syndrome (OR = 1.73, 95% CI: 1.49-2.01), and obesity (OR = 1.62, 95% CI: 1.43-1.85) were associated with a higher HCC risk in individuals with NAFLD. The highest PAF for HCC was observed for pre-existing diabetes (42.1%, 95% CI: 35.7-48.5), followed by metabolic syndrome (28.8%, 95% CI: 21.7-35.9) and obesity (13.2%, 95% CI: 9.6-16.8). The major predisposing factors for HCC in individuals with NAFLD are diabetes mellitus, metabolic syndrome, and obesity, and their control would be critically important in mitigating the rising incidence of NAFLD-related HCC.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36551719</pmid><doi>10.3390/cancers14246234</doi><orcidid>https://orcid.org/0000-0002-8912-9059</orcidid><orcidid>https://orcid.org/0000-0003-2891-3082</orcidid><orcidid>https://orcid.org/0000-0001-7021-9532</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2072-6694 |
ispartof | Cancers, 2022-12, Vol.14 (24), p.6234 |
issn | 2072-6694 2072-6694 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9777437 |
source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Codes Complications and side effects Diabetes Diabetes mellitus Dyslipidemia Enrollments Fatty liver Health aspects Hepatitis Hepatitis C Hepatocellular carcinoma Hepatoma Hypothyroidism Kidney diseases Liver cancer Liver cirrhosis Liver diseases Medicare Metabolic disorders Metabolic syndrome Metabolism Obesity Public health Risk factors Surveillance |
title | Metabolic Risk Factors for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T03%3A17%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metabolic%20Risk%20Factors%20for%20Hepatocellular%20Carcinoma%20in%20Patients%20with%20Nonalcoholic%20Fatty%20Liver%20Disease:%20A%20Prospective%20Study&rft.jtitle=Cancers&rft.au=Antwi,%20Samuel%20O&rft.date=2022-12-17&rft.volume=14&rft.issue=24&rft.spage=6234&rft.pages=6234-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14246234&rft_dat=%3Cgale_pubme%3EA745273678%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2756668569&rft_id=info:pmid/36551719&rft_galeid=A745273678&rfr_iscdi=true |